p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer.

摘要: The tumor suppressor gene p53 and its downstream effector p21 are thought to play major roles in the development of human malignancy. Polymorphic variants at codon 72, 31, have been found be associated with cancer susceptibility, but few studies investigated their effect on prostate risk. In this case-control study, we association 72 31 polymorphisms risk a Taiwanese population. total, 200 patients cancer, 247 age-matched male controls, 181 non–age-matched symptomatic benign prostatic hyperplasia (BPH; American Urological Association symptom score ≥ 8 volume > 20 gm) recruited from two medical centers southern Taiwan were genotyped. Overall, no significant between polymorphism cancer. However, for polymorphism, frequencies Ser / , Arg 52 (26.0%), 85 (42.5%), 63 (31.5%) case patients, 48 (26.5%), 82 (45.3%), 51 (28.2%) BPH 76 (30.8%), 119 (48.2%), (21.1%) respectively. Among cases subjects genotype 1.78-fold increased [95% confidence interval (CI), 1.06-3.01] developing compared those having genotype, after adjusting other potential covariates. This was slightly stronger [odds ratio (OR), 2.13; 95% CI, 1.16-3.92] younger men (≤ years; n = 99 126 respectively) correlated localized disease stage (OR, 1.96; 95 % 1.15-3.35) moderately differentiated 2.04; 1.17-3.53). addition, large volumes (> 50 mL) [OR, 2.29; 1.07-4.98]. Our findings suggest that may enlargement